Acquired Partial Lipodystrophy Associated with Anti-Mi-2 Antibody-positive Adult-onset Dermatomyositis

被引:2
|
作者
Shiraishi, Ken [1 ]
Tohyama, Mikiko [1 ]
Sayama, Koji [1 ]
机构
[1] Ehime Univ, Dept Dermatol, Grad Sch Med, Toon, Ehime 7910295, Japan
关键词
JUVENILE DERMATOMYOSITIS;
D O I
10.2340/00015555-3026
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
[No abstract available]
引用
收藏
页码:95 / 96
页数:2
相关论文
共 50 条
  • [21] The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis
    Oldroyd, Alexander
    Sergeant, Jamie C.
    New, Paul
    McHugh, Neil J.
    Betteridge, Zoe
    Lamb, Janine A.
    Ollier, William E.
    Cooper, Robert G.
    Chinoy, Hector
    Ahmed, Yasmeen
    Armstrong, Raymond
    Bernstein, Robert
    Black, Carol
    Bowman, Simon
    Bruce, Ian
    Butler, Robin
    Carty, John
    Chattopadhyay, Chandra
    Chelliah, Easwaradhas
    Clarke, Fiona
    Dawes, Peter
    Devlin, Joseph
    Edwards, Christopher
    Emery, Paul
    Fordham, John
    Fraser, Alexander
    Gaston, Hill
    Gordon, Patrick
    Griffiths, Bridget
    Gunawardena, Harsha
    Hall, Frances
    Harrison, Beverley
    Hay, Elaine
    Horden, Lesley
    Isaacs, John
    Jones, Adrian
    Kamath, Sanjeet
    Kennedy, Thomas
    Kitas, George
    Klimiuk, Peter
    Knights, Sally
    Lambert, John
    Lanyon, Peter
    Laxminarayan, Ramasharan
    Lecky, Bryan
    Luqmani, Raashid
    Marks, Jeffrey
    Martin, Michael
    McGonagle, Dennis
    McHugh, Neil
    RHEUMATOLOGY, 2019, 58 (04) : 650 - 655
  • [22] Anti-Mi-2 antibody positive myositis: Clinical and histopathological features in three patients
    Honda, M.
    Omoto, M.
    Tanaka, S.
    Kanda, T.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 462 - 463
  • [23] Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis
    Korsten, Peter
    Seitz, Cornelia S.
    Sahlmann, Carsten O.
    Schmidt, Jens
    RHEUMATOLOGY, 2019, 58 (11) : 2071 - 2073
  • [24] Clinical Characteristics of Anti-TIF-1γ Antibody-Positive Dermatomyositis Associated with Malignancy
    Harada, Yumi
    Tominaga, Masaki
    Iitoh, Eriko
    Kaieda, Shinjiro
    Koga, Takuma
    Fujimoto, Kiminori
    Chikasue, Tomonori
    Obara, Hitoshi
    Kakuma, Tatsuyuki
    Ida, Hiroaki
    Kawayama, Tomotaka
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (07)
  • [25] A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency
    Matsuda, Takuya
    Haga, Taiki
    Sakaguchi, Takaaki
    Kan, Toshiaki
    Otsuka, Yasunori
    MODERN RHEUMATOLOGY CASE REPORTS, 2023, 8 (01) : 91 - 94
  • [26] Nuclear matrix protein 2 antibody-positive dermatomyositis associated with hepatocellular carcinoma
    Ueda, Yoshitaka
    Shimada, Kota
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2023, 7 (02)
  • [27] Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis: Reply
    Oldroyd, Alexander
    Sergeant, Jamie C.
    New, R. Paul
    McHugh, Neil J.
    Betteridge, Zoe
    Lamb, Janine A.
    Ollier, William E.
    Cooper, Robert G.
    Chinoy, Hector
    RHEUMATOLOGY, 2019, 58 (11) : 2073 - 2074
  • [28] Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis
    Lin, Rachel R.
    Warp, Peyton V.
    Maderal, Andrea D.
    Elman, Scott A.
    JAMA DERMATOLOGY, 2024, 160 (05) : 575 - 577
  • [29] AC-X: Characteristic Antinuclear Antibody Patterns of Two Anti-Mi-2 Autoantibody-Positive Dermatomyositis Patients-A Case Report
    Wu, Ziyan
    Xu, Honglin
    Zhang, Shulan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] SARS-CoV-2-associated myopathy with positive anti-Mi-2 antibodies: a case report
    Plavsic, Aleksandra
    Arandjelovic, Snezana
    Popadic, Aleksandra Peric
    Bolpacic, Jasna
    Raskovic, Sanvila
    Miskovic, Rada
    HONG KONG MEDICAL JOURNAL, 2023, 29 (02) : 170 - 172